| << Back |
| XenoPort to Present at the Merrill Lynch Healthcare Conference |
| SANTA CLARA, Calif., Jan 29, 2008 (BUSINESS WIRE) -- XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide
access via the World Wide Web to its presentation at the Merrill Lynch
Global Pharmaceutical, Biotechnology and Medical Device Conference.
The live presentation will occur at 5:00 a.m. Pacific Time (8:00 a.m.
Eastern Time) on Wednesday, February 6, 2008. A replay of the
presentation will also be available.
To access the live presentation via the Web, please go to www.XenoPort.com. Please connect to the Web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast. A replay of the Webcast can be accessed for a minimum of one week and will be available approximately 24 hours after the live presentation. About XenoPort XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort's most advanced product candidate, XP13512, has successfully completed two pivotal trials in its Phase 3 clinical program for the treatment of restless legs syndrome and has successfully completed a Phase 2a clinical trial for the management of post-herpetic neuralgia. XenoPort has also reported positive results from a Phase 2a clinical trial of its second product candidate, XP19986, in patients with gastroesophageal reflux disease. To learn more about XenoPort, please visit the Web site at www.XenoPort.com. XenoPort is a registered U.S. trademark. XNPT2G SOURCE: XenoPort, Inc. XenoPort, Inc. Jackie Cossmon, 408-616-7220 ir@XenoPort.com |
| Could not find file '\\us1p-ccsfs01a\Content3\IRXMLDATA\18\187883\Disclaimers.xml'. |